Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Income: 2019-2025

Historic Net Income for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$184.9 million.

  • BridgeBio Pharma's Net Income fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$763.1 million, marking a year-over-year decrease of 85.40%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
  • Per BridgeBio Pharma's latest filing, its Net Income stood at -$184.9 million for Q3 2025, which was down 9.04% from -$169.6 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Net Income ranged from a high of -$19.1 million in Q1 2024 and a low of -$267.4 million during Q4 2024.
  • Moreover, its 3-year median value for Net Income was -$164.3 million (2024), whereas its average is -$150.3 million.
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 86.59% in 2024, then tumbled by 640.71% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Net Income (Quarterly) stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then slumped by 32.37% to -$192.1 million in 2023, then crashed by 39.19% to -$267.4 million in 2024, then declined by 12.59% to -$184.9 million in 2025.
  • Its Net Income stands at -$184.9 million for Q3 2025, versus -$169.6 million for Q2 2025 and -$141.1 million for Q1 2025.